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The native envelope glycoproteins of primary HIV-1 virions have weaker antigenicity than do T-cell laboratory-adapted
(TCLA) viruses. These antigenic properties require further evaluation if recombinant envelope glycoproteins are produced as
part of a vaccine strategy. In this study, we compared the antigenicity of recombinant envelope glycoproteins derived from
three primary isolates (PI) (HIV-1BX08, HIV-1CHA, and HIV-1133) and two TCLA viruses (HIV-1HXB2 and HIV-1MN) produced using the
Semliki Forest virus (SFV) system. This analysis was performed by radioimmunoprecipitation assays and flow cytometry. The
results suggest that the SFV produces envelope glycoproteins with features in common with the envelopes found in naturally
occurring virions. In particular, the PI envelopes had weak heterogeneous antigenic properties. However, the cytometric
analysis also showed that there was less envelope glycoprotein on the cell surface for the PI envelopes than for those of
TCLA viruses, suggesting differences in their intracellular trafficking. The immunogenic properties of the various envelope
glycoproteins were evaluated in mice using recombinant SFV particles as vaccine vectors. The PI envelopes were less
immunogenic than the TCLA envelopes, probably due to both their low antigenicity and cell surface expression level. Thus,
it may be difficult to design an effective vaccine based on native recombinant PI envelopes. © 2000 Academic Press
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CINTRODUCTION
The viral envelope glycoproteins are the main targets
of the various antibody-based vaccine approaches for
protecting individuals against human immunodeficiency
virus type 1 (HIV-1) infection. In their native conformation,
these envelope glycoproteins (gp) form oligomeric
spikes displayed on the virions or on infected cell mem-
branes (Earl et al., 1990). Recent physical and crystallo-
graphic data have suggested that the spike has a trim-
eric organization, consisting of an external envelope gly-
coprotein (gp120) noncovalently associated with a
subunit of a transmembrane envelope glycoprotein
(gp41) trimeric complex (Chan et al., 1997; Weissenhorn
et al., 1997; Wyat et al., 1998). Such oligomeric envelope
complexes have specific antigenic properties, and most
of the epitopes present on monomeric envelope mole-
cules are not available on oligomeric complexes (Burton,
1997; Earl et al., 1994; Fouts et al., 1997; Moore et al.,
995). One determinant factor in vaccine design is elic-
ting antibodies that bind well to these native, oligomeric
1 To whom correspondence and reprint requests should be ad-
ressed at Laboratoire de Virologie, EA 2639, Faculte´ de Me´decine,c
a
niversite´ Franc¸ois Rabelais, 2 bis, Boulevard Tonnelle´, 37032 Tours
edex, France. Fax: (33) 2 47 36 61 26. E-mail: brand@med.univ-tours.fr.
0042-6822/00 $35.00
Copyright © 2000 by Academic Press
All rights of reproduction in any form reserved.
350nvelope complexes. Thus, vaccine strategies in which
he native envelope complexes are presented to the
mmune system are now favored.
Another complicating factor in HIV vaccine design is
aising antibodies against the viruses involved in trans-
ission in humans, the primary viruses. Most primary
iruses isolated from HIV-1-infected humans are mac-
ophage-tropic. These primary isolates (PI) differ from
-cell tropic viruses and their T-cell laboratory-adapted
ariants (TCLA) in terms of the coreceptor used for virus
ntry. The initial steps in virus entry involve the specific
inding of gp120 to the cell surface CD4 receptor and an
nteraction with a chemokine receptor, principally CCR5
r CXCR4 for HIV-1, which serves as coreceptor. PI use
CR5 as a coreceptor (R5 isolates), whereas T-cell tropic
nd TCLA viruses (X4 and X4R5 isolates) are able to use
ther chemokine receptors such as CXCR4 (Alkhatib et
l., 1996; Choe et al., 1996; Feng et al., 1996; Simmons et
l., 1996). In addition to their specific coreceptor usage,
I also have unique antigenic properties. Very little of
heir envelope spike surface is accessible to antibodies
pecific for TCLA viruses (Burton, 1997). In particular, two
ajor epitopes present on TCLA virus envelopes, the
D4 binding domain and the V3 loop, are not very ac-
essible and, consequently, most anti-CD4 binding site
ntibodies and anti-V3 loop antibodies recognize PI en-
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351ANTIGENICITY OF RECOMBINANT HIV-1 ENVELOPE GLYCOPROTEINSvelopes inefficiently (Beddows et al., 1998; Bou-Habib et
al., 1994; Moore et al., 1995; Spenlehauer et al., 1998).
The exposure of epitopes such as the V3 loop on TCLA
viruses probably reflects optimization of the virus–cell
interaction in the absence of the selective pressure en-
countered in vivo by the primary viruses. Only two gp120
epitopes and one gp41 epitope have been shown to be
clearly accessible on PI envelopes. These epitopes are
recognized by the human monoclonal antibodies (mAbs)
IgG1b12, 2G12, and 2F5, respectively (Fouts et al., 1997;
Trkola et al., 1995). The high level of glycosylation of
gp120 and the occlusion by variable loops are often put
forward as reasons for the inaccessibility of epitopes on
the native envelope of PI (Bou-Habib et al., 1994; Reiter et
al., 1998; Wyat et al., 1998).
Thus far, research has focused on the antigenicity of
envelopes from TCLA viruses, which clearly differs from
that of PI envelopes. The challenge of obtaining an im-
munogen that induces antibodies against the mature
oligomeric envelopes of PI remains. Meeting this chal-
lenge requires better characterization of the antigenic
and immunogenic properties of these envelopes.
Vaccine strategies involving the presentation of ma-
ture oligomeric envelopes in vivo are promising because
they should mimic the early phases of interaction be-
tween naturally occurring viruses and their hosts. Thus,
priority is now given to vaccine approaches based on
live attenuated viruses, recombinant viruses expressing
the HIV envelope, genetic vaccines, and purified oligo-
meric glycoproteins (Girard et al., 1997; Richmond et al.,
1998; Robert-Guroff et al., 1998; Shibata et al., 1997;
VanCott et al., 1997).
In this work, we investigated the antigenic and immu-
nogenic properties of envelope glycoproteins derived
from three HIV-1 PI and two TCLA viruses. These enve-
lopes were produced in vitro and in vivo using recombi-
nant Semliki Forest virus (rSFV) RNA and rSFV particles,
respectively (Berglund et al., 1993; Liljestro¨m and Garoff,
1991; Zhou et al., 1994). Our main objective was to as-
sess whether the antigenic properties described as spe-
cific for PI envelopes by comparison with TCLA virus
envelopes would also be found if envelopes were pro-
duced using an expression system such as recombinant
SFV. The SFV system was used for this study because it
has been shown to be one of the most promising vaccine
strategies based on recombinant viruses (Brand et al.,
1998; Mossman et al., 1996).
For antigenic characterization of the envelopes, we
focused on the presentation of neutralizing epitopes cor-
responding to the human neutralizing mAbs F105,
IgG1b12, 447-52D, and 2F5 and we used assays such as
radioimmunoprecipitation and flow cytometry, which re-
spect as much as possible the native conformation of the
envelopes (Conley et al., 1994; Fouts et al., 1997; Roben
et al., 1994; Thali et al., 1991; Trkola et al., 1995). We alsoevaluated the specificity of immune responses in mice
inoculated with rSFV particles expressing each gp160
separately or immunized with a mixture of rSFV particles
expressing the five different gp160s, to assess whether
the simultaneous presentation of different envelopes in
vivo could broaden the specificity of the immune re-
sponse.
RESULTS
Radioimmunoprecipitation assay (RIPA) analysis of
the recombinant envelope glycoproteins
The antigenic properties of the native solubilized re-
combinant envelope glycoproteins from the two HIV-1
TCLA strains (HIV-1HXB2 and HIV-1MN) and the three HIV-1
PI (HIV-1BX08, HIV-1CHA, HIV-1133) were analyzed by RIPA.
The various envelope glycoproteins were produced by
electroporating BHK-21 cells with rSFV RNAs. The glyco-
proteins present in cell lysates and supernatants were
analyzed using a pool of sera from HIV-1-infected indi-
viduals and human neutralizing mAbs F105, IgG1b12,
447-52D, and 2F5. Both full-length gp160 and the pro-
cessed form, gp120, were immunoprecipitated from all
cell lysates and culture supernatants by the human sera
and F105 (Figs. 1A and 1B). However, the amount of
gp120 immunoprecipitated from cell supernatants was
significantly lower for CHA than for envelopes of the
other four strains. Neither the gp160 precursor nor the
mature gp120 of HIV-1133 was bound by IgG1b12. In
contrast, the corresponding epitope was present and
accessible on the envelope precursors of the other four
strains, but was not detectable on the gp120 of HIV-1BX08
(Figs. 1A and 1B). The mAb 447-52D and 2F5 immuno-
precipitated all the gp160s, except the gp160CHA, from the
cell lysates (Fig. 1C). The results obtained with the hu-
man sera and F105 suggest that all five envelope glyco-
proteins were processed and correctly folded, consistent
with previous work, also based on the SFV system
(Brand et al., 1998; Paul et al., 1993). Gp120CHA was
pparently shedded more slowly than the gp120s of the
ther four envelopes although a kinetic analysis should
e performed to confirm this observation. As the SFV
ector constructs were similar for all the envelopes, the
ower shedding observed for the gp120CHA may be due to
a slower processing of this envelope, which remains to
date unexplained. Indeed, the sequence of the cleavage
site was checked and the basic tetrapeptide, REKR, was
present.
There were clear antigenic differences between the
recombinant envelopes. The gp160s of both TCLA
strains (gp160HXB2 and gp160MN) and only one envelope
glycoprotein from the three primary isolates, gp160BX08,
presented all the epitopes recognized by the three neu-
tralizing mAbs IgG1b12, 447-52D, and 2F5 (Figs. 1A, 1B,
and 1C). The IgG1b12 conformational epitope located in
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352 BRAND ET AL.the CD4 binding site region of gp120 was not detected
on gp160133 or on gp120BX08 and gp120133. The mAbs
47-52D and 2F5 are specific for the linear epitopes
PxR, at the center of the V3 loop in gp120, and ELDKWA,
n the ectodomain of gp41, respectively (Conley et al.,
994; Muster et al., 1993). Only the envelope of HIV-1CHA,
which has different amino acid sequences for these two
linear epitopes, was not recognized by 447-52D and 2F5.
FIG. 1. Precipitation of HIV-1HXB2-, HIV-1MN-, HIV-1BX08-, HIV-1CHA-,
HIV-1-infected patients (HIV 1 serum) and by the F105, IgG1b12, 447-52
y transfection of BHK-21 cells with the various rRNAs and were metab
and Methods). (A, C) Precipitation of gp160 from BHK-21 cell lysates; (B
marker.Gp160CHA bears the sequences APGR at the tip of the V3
oop and ELDTWA in the gp41 ectodomain.
t
tlow cytometry analysis of the native recombinant
nvelope glycoproteins
The cell surface expression and the antigenic prop-
rties of five native envelope glycoproteins were ana-
yzed by flow cytometry. The amount of each envelope
lycoprotein produced by BHK-21 or Vero cells was
etermined using a pool of sera from HIV-1-infected
ndividuals (Fig. 2). There were major differences be-
V-1133-recombinant envelope glycoproteins by a pool of sera from
F5 monoclonal antibodies. The envelope glycoproteins were produced
labeled with [35S]cysteine before immunoprecipitation (see Materials
pitation of gp120 from culture supernatants. M.W.M., molecular weightand HI
D, or 2
olicallyween the amounts of TCLA- and PI-derived glycopro-
eins detected on the cell surface. Indeed, the histo-
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353ANTIGENICITY OF RECOMBINANT HIV-1 ENVELOPE GLYCOPROTEINSgrams representing the level of expression of gpHXB2 or
pMN on the surface of BHK-21 cells shift to the right
much more strongly than do the histograms for gpCHA
and gp133 (Fig. 2A). More envelope glycoprotein was
detected on the cell surface for BX08 than for the other
two PI envelopes. The level of gpBX08 was, however,
ower than that of the TCLA glycoproteins. We checked
hat the differences observed were not due to the host
HK-21 cells, by producing envelope glycoproteins in
ero cells. Cell surface expression was evaluated in
he same way, by flow cytometry. The overall level of
xpression was lower than for BHK-21 cells but similar
ifferences in cell surface expression were observed
FIG. 2. Binding of antibodies present in a pool of sera from HIV-1-i
envelope complexes, analyzed by flow cytometry. Data are plotted as flu
the gray area represents transfected or infected cells and the dotted
uninfected Vero cells). (A) BHK-21 cells transfected with the various rRN
(B) Vero cells infected with the various rSFV; Vero cells infected with S
he various rRNAs and permeabilized prior to immunostaining.etween the various envelopes (Fig. 2B). This second
nalysis confirmed that the amounts of glycoprotein
t
fetected on the cell surface with human sera were
arger for TCLA isolates than for PI. We assessed
hether these differences were due to variations in
he overall cellular expression of the various enve-
opes by analyzing permeabilized BHK-21 cells by flow
ytometry, such that intracellular glycoproteins were
lso detected (Fig. 2C). The levels of gpHXB2 and gpMN
detected in permeabilized BHK-21 cells were no
higher than those for gpBX08, gpCHA, or gp133. Thus, there
as no apparent correlation between cell surface de-
ection and overall cellular expression for the various
ecombinant proteins.
The cell surface expression and the antigenic proper-
patients to HIV-1HXB2, HIV-1MN, HIV-1BX08, HIV-1CHA, and HIV-1133 native
nce intensity (x-axis) versus relative cell number (y-axis). In each graph,
presents the mock-transformed cells (untransfected BHK-21 cells or
K-21 cells transfected with RNA.b-gal were used as a negative control;
al were used as a negative control; (C) BHK-21 cells transfected withnfected
oresce
line re
As, BHies of each native recombinant glycoprotein at the sur-
ace of BHK-21 cells were then further analyzed by flow
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354 BRAND ET AL.cytometry using the human mAbs 2F5, F105, IgG1b12,
and 447-52D. The 2F5 epitope was not detected at the
surface of the cells expressing the various envelopes
(data not shown). A similar result was obtained in a
previous study showing that the 2F5 epitope was tem-
perature-dependent and inaccessible at 4°C (Sattentau
et al., 1995). The F105-, IgG1b12-, and 447-52D-specific
epitopes were much more abundant or accessible on the
surface of cells producing TCLA glycoproteins than on
those of cells producing PI glycoproteins (Fig. 3). Of the
recombinant PI envelopes, the F105-, IgG1b12-, and 447-
52D-specific epitopes were more abundant or accessi-
ble on the surface of cells producing gpBX08 than on those
of cells producing gpCHA and gp133, which gave signals
FIG. 3. Binding of human mAbs IgG1b12 (A), F105 (B), and 447-52D
envelope complexes, analyzed by flow cytometry. The envelope glycopr
BHK-21 cells transfected with RNA.b-gal were used as a negative co
umber ( y-axis). In each graph, the gray area represents cells exp
ransformed cells (untransfected BHK-21 cells).ot significantly different from that of the b-galactosidase
ontrol (Figs. 3A, 3B, and 3C).mmunogenicity of native envelope glycoproteins
The immunogenicity of the five native envelope glyco-
roteins was evaluated in BALB/c mice by immunization
ither with rSFV particles producing the various enve-
opes individually or with a mixture of SFV particles
roducing the different envelopes. Mice inoculated with
FV.b-gal particles were used as negative controls. Sera
were collected 50 days after the first immunization and
were tested by envelope-specific enzyme-linked immu-
nosorbent assay (ELISA) for the presence of antibodies
against the homologous and heterologous envelopes.
Cell lysates from BHK-21 cells electroporated with the
various rRNAs were used as a source of envelope gly-
coproteins.
HIV-1HXB2, HIV-1MN, HIV-1BX08, HIV-1CHA, and HIV-1133 native oligomeric
were produced by transfection of BHK-21 cells with the various rRNAs.
ata are plotted as fluorescence intensity (x-axis) versus relative cell
the HIV envelope and the dotted line curve represents the mock-(C) to
oteins
ntrol. DWe checked that equivalent amounts of envelope gly-
coproteins were present in the various cell lysates, by
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355ANTIGENICITY OF RECOMBINANT HIV-1 ENVELOPE GLYCOPROTEINSmeans of controls with two pools of sera from HIV-1-
infected individuals and two pools of sera from unin-
fected individuals (Fig. 4F).
The antibody responses obtained in mice immunized
with the various immunogens were evaluated by deter-
mining antibody titers (Fig. 4). A mean A490 (absorbance
t 490 nm) value was calculated for each group of mice,
t each dilution. The results obtained showed that ani-
als immunized with a single type of envelope tended to
ave the highest antibody titer against the homologous
nvelope, indicating a slightly strain-specific response
Fig. 4). For instance, sera from mice immunized with
SFV.HXB2 had the highest antibody titer (1:3200) against
p160HXB2 (Fig. 4A). Similarly, sera from mice immunized
with rSFV.MN, rSFV.CHA, or rSFV.133 had the highest
antibody titers against gp160MN, gp160CHA, and gp160133,
respectively (Figs. 4B, 4D, and 4E). Antibody titers
against homologous envelopes in mice immunized with
rSFV producing envelopes derived from TCLA viruses
were two to three dilutions higher than those obtained in
mice immunized with rSFV producing envelopes from PI.
The sera collected from mice immunized with the
mixture of rSFVs had the broadest specificity. Indeed,
except in ELISA BX08, the antibody response of the sera
from these mice was always the next strongest after that
of mice immunized with the homologous envelope. Thus,
the antibody response could be broadened by using a
mixture of several envelopes.
The specificity of the ELISAs was checked using
postimmunization sera from mice immunized with SFV.b-
gal. Each serum sample was tested at a 1:100 dilution.
None gave absorbance values above the cut-off point.
The reactivity of postimmunization sera collected from
mice immunized with SFV particles producing the vari-
ous envelopes was also evaluated by ELISA using cell
lysates of BHK-21 cells electroporated with RNA.b-gal.
Each serum sample was tested at a 1:100 dilution. All
absorbance values with this control antigen were below
the cut-off point.
DISCUSSION
Several studies have shown that the oligomeric enve-
lope complexes found on the surface in primary HIV
isolates have specific antigenic properties. In particular,
these envelope complexes have been described as be-
ing less antigenic than the envelope complexes found on
the surface of TCLA viruses (Beddows et al., 1998; Bou-
Habib et al., 1994; Burton, 1997; Moore et al., 1995;
Spenlehauer et al., 1998). Strategies for obtaining an
effective vaccine against HIV are now focusing on the
induction of antibodies recognizing these primary virus
envelope complexes, and vaccine approaches involving
the presentation of native envelope complexes to the
immune system are currently favored (Girard et al., 1997;Richmond et al., 1998; Shibata et al., 1997; Van Cott et al.,
1997). Of the vaccine designs tested recently, ap-
proaches involving live recombinant viruses (i.e., avipox-
viruses, Semliki Forest virus, adenovirus) producing HIV
envelope glycoproteins used alone or in combination
with recombinant soluble envelope glycoproteins in
prime-boost strategies are promising (Brand et al., 1998;
Girard et al., 1997; Robert-Guroff et al., 1998). However,
the different antigenic properties of PI envelope com-
plexes relative to those of TCLA viruses, and their con-
sequences for immunogenicity require further evaluation
if the envelope is to be produced in a heterologous
system such as recombinant viruses.
In this study, we evaluated the antigenic properties of
recombinant envelopes from three PI (HIV-1BX08, HIV-1CHA,
and HIV-1133) and two TCLA viruses (HIV-1HXB2 and
IV-1MN) in the SFV expression system. The antigenic
properties were first analyzed qualitatively by RIPA using
a pool of sera from HIV-1-infected individuals and the
human neutralizing mAbs F105, IgG1b12, 447-52D, and
2F5. Each primary isolate envelope had specific anti-
genic properties. Indeed, all the recombinant envelope
glycoproteins were bound by the human sera and by the
mAb F105 but only one of the three PI envelope glycop-
roteins, that from HIV-1BX08 was recognized by all the
Abs. The RIPA performed with the mAb IgG1b12
howed that the corresponding conformational epitope
as detected only on gp160BX08 (unprocessed) and not on
gp120BX08 (processed). Thus, at least one and possibly
several epitopes recognized by the neutralizing mAbs
tested were missing or hidden on the recombinant en-
velope glycoproteins derived from PI. Furthermore, an
epitope present on gp160 (unprocessed) could be hid-
den on gp120 (processed). Thus, the RIPA results sug-
gested that the antigenicity of the recombinant envelope
glycoproteins derived from PI was weak and heteroge-
neous, consistent with observations made with native
virions (Beddows et al., 1998; Bou-Habib et al., 1994;
Burton, 1997; Moore et al., 1995; Spenlehauer et al.,
1998). The state of processing of the envelope glycopro-
tein should also be taken into account when examining
its antigenic properties. Indeed, an epitope recognized
by a neutralizing antibody such as IgG1b12 may be
hidden on the protein, depending on its state.
We further evaluated the expression and antigenicity
of our recombinant envelope glycoproteins: the native
envelope complexes anchored to the external surface of
the cellular membrane were analyzed by cytometry using
a pool of sera from HIV-1-infected individuals and the
human mAbs F105, IgG1b12, 447-52D, and 2F5. The
results obtained with human sera showed that less en-
velope glycoprotein was produced on the surface of
BHK-21 cells for PI than for TCLA viruses. For PI enve-
lopes, the level of cell surface expression was very low
for gpCHA and gp133, whereas gpBX08 had an intermediate
356 BRAND ET AL.FIG. 4. Titration of anti-gp160 antibody response in sera from groups of mice immunized with rSFV.HXB2 (HXB2 mice), rSFV.MN (MN mice),
rSFV.BX08 (BX08 mice), rSFV.CHA (CHA mice), rSFV.133 (133 mice), or a mixture of the five rSFV particles (MIX mice), by envelope-specific enzyme
immunoassays. The envelopes captured on the solid phase were obtained from lysates of BHK-21 cells transfected with rRNA.HXB2 (A), rRNA.MN
(B), rRNA.BX08 (C), rRNA.CHA (D), or rRNA.133 (E). Each group of mice is represented by a different symbol. Each point corresponds to the mean
absorbance value for sera from each group at the corresponding dilution. We checked that similar amounts of envelope glycoprotein were captured
on the solid phase from the various cell lysates, by carrying out an ELISA under similar conditions, using two pools of sera from HIV-1-infected patients
and two pools of sera from uninfected patients (F). Sera were tested at a 1:100 dilution.
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357ANTIGENICITY OF RECOMBINANT HIV-1 ENVELOPE GLYCOPROTEINSlevel of expression, between those of gpCHA or gp133 and
hose of TCLA envelopes. These apparent differences in
ell surface expression between the various envelope
lycoproteins were confirmed in Vero cells, indicating
hat they were not related to a particular cell type. The
ifferences observed may be due to differences in the
xpression levels of the various envelope glycoproteins
n the cell surface or to specific antigenic properties of
he primary isolate envelopes. Cytometric analysis with
ermeabilized BHK-21 cells showed that the overall level
f expression for PI envelopes was not lower than that of
CLA virus envelopes. So, the differences observed be-
ween the expression levels of the five envelopes studied
ere not due to differences in the overall cellular expres-
ion between the envelope glycoproteins. Cytometric
nalysis with mAbs showed only weak detection of the
arious PI envelopes on the BHK-21 cell surface. The
evel of binding of mAbs to the surface of cells express-
ng the PI envelope gpBX08 was intermediate between that
of cells expressing gpCHA or gp133 and those expressing
TCLA envelopes, consistent with the results obtained
with the pool of human sera. Similar results were ob-
tained in cytometric analysis with another pool of human
sera from HIV-1-infected patients and the serum of pa-
tient CHA (data not shown). The similarity of the results
obtained for the various envelopes with the human sera
that, by definition, recognize several epitopes simulta-
neously and the mAbs that are specific for a single
epitope strongly suggests that envelopes from PI have a
less cell-surface-specific pattern of expression. These
differences in cell surface expression as well as the
weak level of mAbs binding to the surface of cells ex-
pressing the PI envelope glycoproteins did not allow the
antigenic properties of the various recombinant enve-
lopes under their native configuration to be compared.
The low levels of cell surface expression of PI enve-
lope glycoproteins may be due at least in part to the
kinetics of viral replication of the various viruses used to
clone env genes. HIVcha and HIV133 PI replicate to only
ow levels in cultured PBMCs in vitro. HIVBX08, the recom-
inant envelope of which was expressed at the cell
urface to a higher level than was observed with the
ther PI, replicates more efficiently in peripheral blood
ononuclear cells (PBMCs). Virus titers were usually
rom 103 to 104 infectious units per milliliter (IU/ml) of
ulture supernatant. The highest levels of expression on
he cell surface were observed with TCLA virus enve-
opes. These viruses have high replicative capacities
nd titers exceeding 105 IU/ml of culture supernatant are
sually obtained. Could the transportation of the PI en-
elope from the cell cytoplasm to the cell membrane be
ssociated with a downregulation of the replication rate
f the viruses? This phenomenon can hardly be shown in
ells replicating HIV because many factors interfere with
irus growth. In the SFV system, the recombinant RNAsare strictly similar except for the sequence of the env
enes. Consequently, the differences in cell surface ex-
ression can only be due to the amino acid sequence of
he envelope. All the sequences of the most important
ignals described as being involved in intracellular traf-
icking and endocytosis of the HIV envelope glycopro-
eins were similar in the PI- and TCLA-derived envelope
lycoproteins (Berlioz-Torrent et al., 1999). Thus, the sig-
al involved in the differences of cell surface expression
etween the PI- and TCLA-derived envelope glycopro-
eins included in this study remains to be identified.
owever, our current research performed using chimeric
nvelope glycoproteins (i.e., gp41MN/gp120133) indicates
hat such a retention and/or reinternalization signal is
ocated within the transmembrane envelope glycoprotein
gp41) of the PI (Lebigot et al., manuscript in preparation).
n addition, it will be of interest in further studies to
etermine whether our different recombinant envelope
lycoproteins expressed using the SFV system are able
o complement infection. We already showed that cells
xpressing some of these recombinant envelope glyco-
roteins can fuse and produce syncytia with CD4-posi-
ive cells (Verrier et al., 1999).
RIPA and cytometry studies showed that TCLA virus
envelopes differed from PI envelopes in antigenicity and
in expression levels at the cell surface. The effects on
immunogenicity of these specific properties were evalu-
ated in BALB/c mice after immunization with rSFV parti-
cles producing the various envelopes individually or with
a mixture of rSFV particles producing the various enve-
lopes. Antibody responses were analyzed quantitatively
by envelope-specific ELISAs. These ELISAs were per-
formed using cell lysates from electroporated BHK-21
cells as a source of envelope glycoproteins. The enve-
lope glycoproteins in cell lysates were unprocessed and
had both gp120 and gp41 epitopes. These recombinant
antigens were used in preference to the native envelope
glycoproteins derived from virions because the replica-
tion rate of HIVCHA and HIV133 in cultured PBMCs was too
low for production of the minimum amount of protein
required for ELISA. The control ELISAs performed with
two pools of human sera from HIV-1-infected patients
showed that (i) the epitope recognized by the anti-gp120
sheep polyclonal capture antibody D7324 was present
and accessible on the various envelopes and (ii) the
amounts of envelope glycoprotein captured on the solid
phase were similar in all cases. The results of the
ELISAs led to three conclusions. First, the immune re-
sponses obtained in the groups of mice immunized with
the various envelopes were slightly strain-specific. Sec-
ond, the antibody titers against homologous envelopes
were two to three dilutions higher in mice immunized
against TCLA virus envelopes than in mice immunized
against PI envelopes, showing that PI recombinant gly-
coproteins are more weakly immunogenic. The weak cell
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358 BRAND ET AL.surface expression of the PI envelope, as shown by
cytometric analysis, could have consequences for the
intensity of the humoral immune response although cells
expressing the envelope in vivo probably undergo lysis
and release the intracellular envelope. Third, the hu-
moral immune response against the HIV envelope can
be broadened by simultaneous immunization with enve-
lope glycoproteins derived from different strains. Similar
ELISAs were also performed with the mature gp120
found in the culture supernatants of electroporated
BHK-21 cells. The results showed that the weak immu-
nogenicity of PI envelopes was most pronounced if only
gp120 epitopes were available on the solid phase (data
not shown), which renders difficult the comparison of the
results.
The results presented herein suggest that the SFV
system produces HIV envelope antigens that have fea-
tures in common with the native antigens on naturally
occurring virions: PI envelopes generally have weaker
and more variable antigenicity than TCLA envelopes. Our
study also suggests that some PI envelopes may be less
expressed on the cell surface than TCLA virus enve-
lopes. Obviously, this phenomenon does not lower the
density of envelope glycoproteins present on virion par-
ticles since previous reports showed a higher density of
envelope glycoproteins present on virions for PI by com-
parison with TCLA strains (Sullivan et al., 1995; Willey et
al., 1994). However, this phenomenon may be indirectly
involved, along with the lower accessibility of the neu-
tralizing epitopes on PI envelope glycoproteins, in the
escape of HIV-1 PI-infected cells from the immune sys-
tem in vivo.
The weak antigenicity of recombinant PI envelope
antigens raises the question whether these PI antigens
could induce better neutralizing antibodies than the al-
ready tested TCLA envelope immunogens, which have
given disappointing results.
MATERIALS AND METHODS
Virus and provirus DNAs
We studied three PI (BX08, CHA, and 133) and two
TCLA strains (MN and HXB2) of HIV-1. The coreceptor
usage of the PI was determined only for HIVBX08, which
ses the CCR5 coreceptor (determination by F. Barre´-
inoussi, Institut Pasteur, Paris; personal communica-
ion). For the other two primary viruses, the viral titers
btained after culture in vitro with mitogen-activated
PBMCs were too low for determination of coreceptor
usage. The PI BX08 and CHA were isolated soon after
seroconversion (within 6 months). BX08 was provided by
H. Fleury and I. Pellegrin (Centre Hospitalier Universita-
ire Pellegrin, Bordeaux, France). The virus was amplified
by one passage in mitogen-stimulated PBMCs from se-
ronegative donors to obtain infected cells for DNA ex-traction (Moog et al., 1997). Cellular DNA was extracted
from cultured PBMC 1 week after infection, using the
Wizard genomic DNA purification kit (Promega, Madison,
WI). CHA was obtained by coculture of PBMCs from an
HIV-infected individual with mitogen-stimulated PBMCs
from seronegative donors (Hollinger et al., 1992). Viral
growth was assessed by monitoring the release of p24
into the culture supernatant, using a commercial kit (Vi-
ronostika HIV-1 antigen, Organon Technika, Oss, The
Netherlands). Cellular DNA was extracted from cultured
PBMCs harvested after 18 days of culture, using the
Wizard genomic DNA purification kit. For the third pri-
mary virus (133), cellular DNA was extracted directly from
Ficoll-Hypaque-fractionated PBMCs of an infected indi-
vidual in the acute phase of a primary infection before
seroconversion, using the Wizard genomic DNA purifica-
tion kit. Therefore, the env gene of BX08 was cloned from
primary isolate that was passaged several times in
itro in PBMCs, the env gene of CHA was cloned from
roviral DNA as soon as the coculture of PBMCs showed
igns of replication (detection of p24 in the supernatant),
nd the env gene of 133 was cloned directly from the
uncultured PBMCs of the patient.
For the TCLA HIV-1MN, an aliquot of infectious culture
upernatant was incubated with SupT1 cells at 37°C for
h. The cells were pelleted and resuspended at a
ensity of 106 cells/ml in RPMI containing 10% heat-
inactivated fetal calf serum (FCS) and maintained at
37°C under 5% CO2. Cellular DNA was extracted after 7
days of culture, using the Wizard genomic DNA purifica-
tion kit. The HXB2 clone was already available in the
laboratory (Fisher et al., 1985).
SFV vector construction
PCR amplification of the entire HIV-1HXB2 env gene and
the construction of the expression vector pSFV-HXB2
have been described elsewhere (Brand et al., 1998). All
the other env genes were amplified from DNA extracted
from the cultured cells or directly from the uncultured
PBMCs for patient 133. Nested PCR was required to
obtain enough amplification product for further subclon-
ing. Various sets of primers were used depending on the
env gene to be amplified. The env genes from HIV-1MN,
HIV-1BX08, and HIV-1CHA were amplified with the primers
59-CCAGTAGATCCTAGACTAGAGCCC-39) and (59-TG-
ATTGCTACTTGTGATTGCTCC-39) for the first round, and
59-AGGATCCGAAGACAGGCACCATGAGAGTGAAGG-39)
nd (59-GGGATCCATCTTATAGCAAAGCCCTTTCCAA-39)
or the second round. The inner primers were designed
o generate a BamHI site at both ends of the amplified
ragment. The env gene of HIV-1133 was initially amplified
using the primers (59-AGAAAGAGCAGAAGACAGTG-39)
and (59-ATTGCTACTTGTGATTGCT-39) for the first round,
and (59-ATTGTCGACTGGCAATGAGAGTGAAGGAG-39)
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he second round. BamHI sites were then created by an
dditional round of PCR amplification using the following
rimers: (59-CGGATCCTTGTCGACGCACCATGAGAGTG-
AG-39) and (59-GGGATCCATCTTATAGCAAAGCCCTT-
CCAA-39). All PCR products were inserted into pCRII
sing the TA cloning system (Invitrogen, Carlsbad,
A). The expression vectors pSFV.HXB2, pSFV.MN,
SFV.BX08, pSFV.CHA, and pSFV.133 were constructed by
nserting the corresponding env gene fragment into the
amHI site of the pSFV1 vector (Life Technologies, Rock-
ille, MD). All env genes inserted into pSFV1 were se-
quenced and no significant change was detected in the
various sequences. All these viruses were of subtype B.
Preparation of recombinant SFV RNA and SFV
particles
Recombinant RNA.HXB2, RNA.MN, RNA.BX08,
RNA.CHA, and RNA.133 encoding the full-length gp160
glycoproteins were synthesized in vitro, using the vari-
us expression vectors as templates. For the control,
ecombinant RNA.b-gal, encoding the b-galactosidase
protein, was synthesized from the expression vector,
pSFV3 (Life Technologies, Rockville, MD). The recombi-
nant RNAs (rRNAs) were synthesized in vitro according
to the protocol provided by the manufacturer and the
RNA samples were then stored at 280°C.
Recombinant SFV particles were constructed with
pSFVhelper2 (kindly provided by P. Liljestro¨m, Karolinska
Institute, Stockholm, Sweden). The pSFVhelper2 vector
was used as a template for the in vitro synthesis of a
recombinant RNA derived from the structural genes of
SFV. This RNA was used with each of the recombinants,
RNA.HXB2, RNA.MN, RNA.BX08, RNA.CHA, RNA.133, and
RNA.b-gal, to cotransfect BHK-21 cells, so as to produce
ecombinant SFV.HXB2, SFV.MN, SFV.BX08, SFV.CHA,
FV.133, and SFV.b-gal particles (for more details, see
Berglund et al., 1993; Brand et al., 1998; Liljestro¨m and
aroff, 1991; Zhou et al., 1994). Recombinant virus stocks
ere stored at 280°C. The titers of the recombinant
irus stocks were determined using Vero cells as de-
cribed previously (Brand et al., 1998). Titers are ex-
ressed as infectious units per milliliter.
adioimmunoprecipitation assays
BHK-21 cells (107 per transfection) were electropo-
rated (350 V, 750 mF) with 5 mg of each rRNA, plated in
75-cm2 tissue culture flasks, and labeled in cysteine-free
medium containing 5% heat-inactivated FCS and 40 mCi
of [35S]cysteine per milliliter. The cells were incubated for
16 h at 37°C and lysed with Nonidet-P40 buffer [0.5%
Nonidet-P40, 0.5 M NaCl, 10 mM Tris–HCl (pH 7.5)].
Culture supernatants (800 ml/reaction) and cell lysates
(80 ml/reaction corresponding to 3 3 105 cells) weremmunoprecipitated with a pool of sera from HIV-1-in-
ected individuals (5 ml/reaction) or human mAb F105 (2
mg/reaction; gift from L. Cavacini and M. Posner, Beth
Israel Deaconess Medical Center, Boston, MA), recom-
binant mAb IgG1b12 (2 mg/reaction; gift from D. Burton,
The Scripps Research Institute, La Jolla, CA), mAb 447-
52D (2 mg/reaction; gift from S. Zolla-Pazner, New York
University School of Medicine, New York, NY), or mAb
2F5 (2 mg/reaction, gift from H. Katinger, Institute of
Applied Microbiology, University of Agriculture, Vienna,
Austria). The F105 and IgG1b12 mAbs react with confor-
mational epitopes overlapping the CD4 binding site of
gp120 (Roben et al., 1994; Thali et al., 1991). The 447-52D
antibody binds to the V3 determinant of gp120 (Conley et
al., 1994). The 2F5 recognizes an epitope located on the
ectodomain of gp41 (Muster et al., 1993). For IgG1b12, a
econdary anti-human IgG antibody (Fab specific, Sigma,
t. Louis, MO) was required. The immunoprecipitated
roteins were incubated with protein A-conjugated
epharose CL4-B beads (Pharmacia, Uppsala, Sweden;
mg/reaction) for 18 h at 4°C. They were washed three
imes with Nonidet-P40 buffer, separated by electro-
horesis in 10% SDS–polyacrylamide gels, and detected
y autoradiography. Independent experiments, including
nvelope expression and RIPA with the pool of human
era and the mAbs were repeated at least twice for each
nvelope.
mmunofluorescence and flow cytometry analyses
Analyses were conducted on BHK-21 cells electropo-
ated with RNA, with or without permeabilization of the
ell membrane, and on SFV-infected Vero cells as fol-
ows. Nonpermeabilized BHK-21 cells (107 per transfec-
ion) were electroporated (350 V, 750 mF) with 5 mg of
each rRNA and plated in 75-cm2 tissue culture flasks.
he cells were incubated for 16 h at 37°C, harvested,
ashed once in PBS, pelleted, and resuspended at a
ensity of 106 cells per 100 ml in ice-cold PBS containing
2% bovine serum albumin (PBS–BSA). Cell suspensions
(100 ml) were incubated for 30 min at 4°C with a pool of
sera from HIV-1-infected individuals (0.5 ml/reaction) or
ith human mAbs F105 (5 mg/reaction), IgG1b12 (2.5
mg/reaction), 447-52D (2.8 mg/reaction), or 2F5 (10 mg/
reaction). The concentrations of mAbs used were satu-
rating, as determined in preliminary experiments, except
for the 447-52D antibody, which was not purified (culture
supernatant) and for which larger amounts were not
available. The cells were washed twice in ice-cold PBS–
BSA and incubated for 30 min at 4°C with a FITC-labeled
anti-human IgG (Fab) conjugate (Cappel/ICN, Costa
Mesa, CA) diluted 1:1500 in PBS–BSA. The cells were
washed twice in ice-cold PBS–BSA, pelleted, resus-
pended in 500 ml of ice-cold PBS–BSA, and immediately
analyzed by flow cytometry in a Beckon Dickinson FAC-
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360 BRAND ET AL.Star Plus flow cytometer (Beckon Dickinson, San Jose,
CA) with Cellquest software. Permeabilized cells were
treated with the IntraPrep Permeabilization Reagent (Im-
munotech, Marseille, France) just before staining and
were stained as described above except that all incuba-
tions were at room temperature. Cytometry of permeabil-
ized cells was carried out only with the pool of sera from
HIV-1-infected individuals.
For cytometric analysis of infected Vero cells, the cells
were seeded at 5 3 106 cells per 75-cm2 culture flask.
hey were incubated for 12 h and then infected with the
arious activated rSFV particles at a multiplicity of infec-
ion of 5 infectious particles per cell (Brand et al., 1998).
he cells were incubated for 16 h at 37°C, treated as
escribed for nonpermeabilized BHK-21 cells, and imme-
iately analyzed by flow cytometry. Envelope glycopro-
ein antigen recognition was analyzed only with the pool
f human sera.
mmunization protocols
Seven different immunization protocols were used,
ach on a group of six 8-week-old BALB/c mice. In the
irst (HXB2 mice), second (MN mice), third (BX08 mice),
ourth (CHA mice), and fifth protocols (133 mice), animals
ere inoculated three times with 106 IU of SFV.HXB2,
SFV.MN, SFV.BX08, SFV.CHA, and SFV.133 particles, re-
spectively. In the sixth protocol (MIX mice), animals were
inoculated three times with a mixture (SFV.MIX) contain-
ing 0.2 3 106 IU of each of the 5 rSFV particles. In the
seventh protocol (b-gal mice), mice were inoculated
hree times with 106 IU of SFV.bgal as a control. Inocu-
lations with SFV particles were performed on days 0, 14,
and 36 for each protocol. For each inoculation, SFV
particles were activated as previously described (Brand
et al., 1998), diluted to 107 IU/ml in Dulbecco’s phos-
phate-buffered saline (Sigma), and 100 ml of viral sus-
pension was immediately injected intramuscularly into
the thigh of the mouse. Blood samples were collected on
days 0 and 50 and mouse sera were stored at 220°C
until used for antibody testing.
Envelope-specific enzyme immunoassays
Sera collected from mice treated according to the
various protocols were tested by envelope-specific
ELISAs for antibodies against the homologous envelope
or heterologous envelopes. The envelope-specific ELISA
protocol used was derived from the procedure initially
described by Moore et al. (1994). BHK-21 cells (107 per
ransfection) were electroporated (350 V, 750 mF) with the
rRNAs (5 mg per transfection) encoding each of the
various envelopes, to provide a source of envelope gly-
coproteins. BHK-21 cells electroporated with RNA.b-gal
were used as a negative control. After electroporation,
the cells were plated in 75-cm2 tissue culture flasks and
a
Fwere incubated for 16 h at 37°C. The culture superna-
tants were removed. The cells were washed once with
PBS and lysed by incubation with 1% Nonidet-P40 in PBS
(2 ml/75-cm2 flask). The cell lysates were centrifuged at
15,000 g for 15 min to remove cell debris. The cell lysates
were aliquoted and kept frozen at 280°C until use.
Luxlon plates (CML, Nemours, France) were coated (100
ml/well) by incubation overnight at 4°C with a 1 mg/ml
solution of anti-gp120 sheep polyclonal antibody D7324
(Aalto, Dublin, Ireland) in Tris-buffered saline [TBS; 100
mM Tris-HCl (pH 7.5), 150 mM NaCl]. The plates were
washed three times with TBS containing 0.5% Tween 20
(TBS-T). Nonspecific binding sites were saturated by
incubation for 1 h at room temperature with 200 ml of 2%
ewborn calf serum (NBCS) in TBS. Envelope glycopro-
eins were captured on the solid phase by incubation for
h at room temperature with 100 ml of cell lysate (diluted
1:10 in TBS containing 10% NBCS and 1% Nonidet-P40).
The plates were washed five times with TBS-T. Sera
collected from mice were diluted in TBS containing 0.5%
Tween 20, 20% sheep serum, and 10% NBCS (TBS.T.S.N)
and 100 ml of each dilution was added to individual wells.
series of 1 in 2 dilutions, from 1:100 to 1:12,800, were
nalyzed for postimmunization sera collected on day 50,
hereas preimmunization sera collected on day 0 were
ested only at a dilution of 1:100. The plates were incu-
ated for 1 h at room temperature and washed five times
ith TBS-T. A goat anti-mouse Ig (Biosource, Camarillo,
A) conjugated with peroxidase and diluted 1:5000 in
BS.T.S.N was added (100 ml/well). The plates were in-
ubated for 30 min at room temperature and washed
hree times with TBS.T and 100 ml of a mixture of H2O2
and o-phenylene-diamine was added. The plates were
left for 30 min at room temperature in the dark and the
color development was then stopped by adding 50 ml of
2 N H2SO4. Absorbance at 490 nm was determined.
Antibody titers are expressed as the highest dilution
giving an A490 value greater than 0.04 for all ELISAs. The
ut-off point was determined by testing the preimmuni-
ation samples collected from 36 mice at a dilution of
:100. Each postimmunization sample was tested by
LISA HXB2, ELISA MN, ELISA BX08, ELISA CHA, and
LISA 133 with envelope glycoproteins from cell lysates
f BHK-21 cells electroporated with the corresponding
RNA. The mean absorbance with preimmunization sera
as 0.011 (SD 0.003). The cut-off value therefore corre-
ponded to the mean absorbance value plus 10 SD.
We determined whether the envelope glycoproteins
erived from cell lysates were uncleaved gp160 or ma-
ure gp120 by probing with three murine mAbs specific
or the gp120 or the gp41. The anti-gp120 antibody was
F6C12 (gift from N. Piga, BioMe´rieux). The anti-gp41
ntibodies were 13E5F8 (gift from N. Piga, BioMe´rieux)
nd mAb 1577 (Intracell/Neosystem, Strasbourg,
rance). These mAbs were tested at a concentration of
EE
F
F
F
G
H
L
M
M
M
M
M
P
R
361ANTIGENICITY OF RECOMBINANT HIV-1 ENVELOPE GLYCOPROTEINS20 mg/ml in the various ELISA formats. As expected, the
cell lysates contained both the gp120 and the gp41
epitopes. We checked whether the amount of envelope
glycoprotein captured on the solid phase was similar
regardless of the rRNA used. Envelope-specific ELISAs
were carried out with two pools of sera from HIV-1-
infected patients and two pools of sera from uninfected
patients as negative controls (all at 1:100 dilution). A goat
anti-human Ig (Biosource) conjugated with peroxidase
was used as the secondary antibody.
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